Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Distinct Neutralizing Antibody Escape of SARS-CoV-2 Omicron Subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2
Panke Qu, John P. Evans, Julia N. Faraone, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 80

Showing 1-25 of 80 citing articles:

Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2
Panke Qu, John P. Evans, Julia N. Faraone, et al.
Cell Host & Microbe (2022) Vol. 31, Iss. 1, pp. 9-17.e3
Open Access | Times Cited: 236
Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution
Yunlong Cao, Fanchong Jian, Jing Wang, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 212
Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants
Panke Qu, Julia N. Faraone, John P. Evans, et al.
Cell Reports (2023) Vol. 42, Iss. 5, pp. 112443-112443
Open Access | Times Cited: 144
Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents
Yunlong Cao, Fanchong Jian, Zhiying Zhang, et al.
Cell Reports (2022) Vol. 41, Iss. 12, pp. 111845-111845
Open Access | Times Cited: 96
Epistasis lowers the genetic barrier to SARS-CoV-2 neutralizing antibody escape
Leander Witte, Viren A. Baharani, Fabian Schmidt, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 58
A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates
Payton A. Weidenbacher, Mrinmoy Sanyal, Natalia Friedland, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 56
SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines
Shanti Pather, Shabir A. Madhi, Benjamin J. Cowling, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 49
Longitudinal outcomes of COVID-19 in solid organ transplant recipients from 2020 to 2023
Javier T Solera, Berta G. Árbol, Ankit Mittal, et al.
American Journal of Transplantation (2024) Vol. 24, Iss. 7, pp. 1303-1316
Open Access | Times Cited: 16
Challenges and developments in universal vaccine design against SARS-CoV-2 variants
Fangxin Zhao, Xiaodong Zai, Zhiling Zhang, et al.
npj Vaccines (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 56
Omicron BQ.1 and BQ.1.1 escape neutralisation by omicron subvariant breakthrough infection
Xiaolin Jiang, Ka-Li Zhu, Xuejun Wang, et al.
The Lancet Infectious Diseases (2022) Vol. 23, Iss. 1, pp. 28-30
Open Access | Times Cited: 44
Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1
David J. Sullivan, Massimo Franchini, Jonathon W. Senefeld, et al.
Journal of General Virology (2023) Vol. 104, Iss. 5
Open Access | Times Cited: 30
Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration
Dean Follmann, Meagan P. O’Brien, Jonathan Fintzi, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 26
SARS-CoV-2 Omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors
Shuai Xia, Lijue Wang, Fanke Jiao, et al.
Emerging Microbes & Infections (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 24
SARS-CoV-2 omicron variants harbor spike protein mutations responsible for their attenuated fusogenic phenotype
Seung Bum Park, Mohsin Khan, Sai Chaitanya Chiliveri, et al.
Communications Biology (2023) Vol. 6, Iss. 1
Open Access | Times Cited: 24
Antigenic evolution of SARS coronavirus 2
Anna Z. Mykytyn, Ron A. M. Fouchier, Bart L. Haagmans
Current Opinion in Virology (2023) Vol. 62, pp. 101349-101349
Open Access | Times Cited: 24
SARS-CoV-2 Omicron (B.1.1.529) Variant: A Challenge with COVID-19
Zeinab Mohseni Afshar, Ali Tavakoli Pirzaman, Bardia Karim, et al.
Diagnostics (2023) Vol. 13, Iss. 3, pp. 559-559
Open Access | Times Cited: 23
Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in nonhuman primates
Nanda Kishore Routhu, Samuel D. Stampfer, Lilin Lai, et al.
Science Immunology (2023) Vol. 8, Iss. 88
Open Access | Times Cited: 22
Next-generation treatments: Immunotherapy and advanced therapies for COVID-19
Jenny Andrea Arévalo-Romero, Sandra M. Chingaté-López, Bernardo Camacho, et al.
Heliyon (2024) Vol. 10, Iss. 5, pp. e26423-e26423
Open Access | Times Cited: 8
Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies
Delphine Planas, Timothée Bruel, Isabelle Staropoli, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 31
Global threat from novel SARS-CoV-2 variants, BF.7, XBB.1.5, BQ.1, and BQ.1.1: variants of concern?
Ryan Varghese, Dileep Kumar, Rohit Sharma
Human Cell (2023) Vol. 36, Iss. 3, pp. 1218-1221
Open Access | Times Cited: 16
Immunogenicity and Safety of Bivalent Recombinant Protein COVID-19 Vaccine ZF2202: A Randomized, Open-label, Positive-controlled Trial
Huaiyu Yang, Ping Wang, Qiang Wu, et al.
Heliyon (2025), pp. e43100-e43100
Open Access
Genetic and Structural Data on the SARS-CoV-2 Omicron BQ.1 Variant Reveal Its Low Potential for Epidemiological Expansion
Fabio Scarpa, Daria Sanna, Domenico Benvenuto, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 23, pp. 15264-15264
Open Access | Times Cited: 26
Baseline Sequencing Surveillance of Public Clinical Testing, Hospitals, and Community Wastewater Reveals Rapid Emergence of SARS-CoV-2 Omicron Variant of Concern in Arizona, USA
Matthew F. Smith, Steven C. Holland, Mihyun B. Lee, et al.
mBio (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 13
Serum neutralization of SARS‐CoV‐2 Omicron BA.2, BA.2.75, BA.2.76, BA.5, BF.7, BQ.1.1 and XBB.1.5 in individuals receiving Evusheld
Qianqian Zhao, Xin Wang, Ze Zhang, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 7
Open Access | Times Cited: 13
COVID-19: From emerging variants to vaccination
Thilini H. Senevirathne, Demi Wekking, Joseph W. R. Swain, et al.
Cytokine & Growth Factor Reviews (2023) Vol. 76, pp. 127-141
Closed Access | Times Cited: 12
Page 1 - Next Page

Scroll to top